Trefoil Therapeutics Selects AGC Biologics as Primary Manufacturer for TTHX1114, an Engineered FGF-1 Therapy for Corneal Diseases

SEATTLE, Feb. 4, 2020 /PRNewswire/ -- Global biopharmaceutical contract development and manufacturing organization (CDMO)AGC Biologicsand Trefoil Therapeutics announced the execution of a manufacturing contract to supply its lead product, TTHX1114. Trefoil is developing this engineered form of FGF-1 to restore vision in patients with corneal diseases by regenerating corneal tissue.

After a three-month selection process, Trefoil Therapeutics selected AGC Biologics for its deep technical expertise and proven capabilities in cGMP manufacturing of protein therapeutics from preclinical through commercial production. Dr. David Eveleth, CEO of Trefoil Therapeutics, commented, “AGC Biologics’ extensive experience in cGMP manufacturing makes it the ideal partner to help us advance the development of TTHX1114. Our engineered form of FGF-1 is expected to enter clinical trials in 2020 as an investigational medicinal product for the treatment of corneal endothelial dystrophy, and we believe it has the potential to significantly impact patients’ lives.”

Patricio Massera, CEO of AGC Biologics, stated, “AGC Biologics is pleased to support Trefoil Therapeutics in the manufacturing of this life-changing product. Our teams will work together in an open and collaborative manner, and we are excited about the potential of this project.”

AGC Biologics’ global manufacturing footprint includes a cGMP-compliant facility in Heidelberg, Germany, which will begin production of TTHX1114 in the coming months.